CD274 and hepatocellular carcinoma: Here, we found HBV reactivates SALL4 which then improves HCC progress through STAT3-SALL4-miR-200c-PD-L1 pathway, especially strongly evidenced by HBV-persistent mouse model and human HCC patients.